Question Bank › Scarcity premium: the thing the company sells is

Scarcity premium: the thing the company sells is becoming harder to get, and management is letting the…

Scarcity premium: the thing the company sells is becoming harder to get, and management is letting the shortage do the s

Calls Tested
484
Answered YES
12
Hit Rate
2.5%
rare by design

Arrowhead Pharmaceuticals, Inc. (ARWR) — this company's answers

NO on the Q4 2022 call 2022-11-28 D
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that what the company sells is becoming harder for buyers to obtain, and that management is allowing that tightening to work in its favor. The transcript is about Arrowhead Pharmaceuticals, a biotech company developing RNAi therapeutics. They have various drug candidates in clinical trials. The question is about availability of their product/service/capacity etc. In biotech, the "product" is the drug candidates, but they are not yet on the market. The company is developing drugs, not selling them yet. The concept of "buyers" would be patients or partners? They have partnerships with other companies (Takeda, Amgen, etc.) for licensing. But the question is about the company's own product becoming harder to obtain. Since they are a development-stage company, they don't have commercial products yet. They are conducting clinical trials. The scarcity might refer to capacity in manufacturing? They mention capital expenditures for GMP manufacturing. But they don't talk about buyers competing for their output. They talk about their pipeline and progress. They mention "20 in '25" plan. They talk about monetizing royalties. There is no mention of availability tightening for buyers. They are not selling a product that is in short supply. They are developing drugs. The only possible interpretation is that they have limited manufacturing capacity? But they don't discuss that as a constraint on buyers. They discuss their own financial resources and partnerships. The question is clearly about a business where the company sells something and buyers are finding it harder to get. This doesn't apply to a clinical-stage biotech. So the answer is NO. We need to be careful: The transcript might have some mention of "supply" or "capacity" but it's about their own manufacturing expansion. They say "capital expenditures up to $200 million as we near completion on our footprint expansion projects, including GMP manufacturing." That is about adding capacity, not scarcity. They don't say that buyers are waiting. They don't mention any shortage of their product. They are not selling anything yet. So the answer is NO. Thus, answer NO.

← Back to the full ARWR analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management convey that WHAT THE COMPANY SELLS IS BECOMING HARDER FOR BUYERS TO OBTAIN — that availability of the company's own product, service, capacity, slots, units, or expertise is tightening relative to what buyers want — AND that management is allowing that tightening to work in the company's favor, rather than racing to eliminate it? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation as a present-tense reality: buyers who want what the company offers are finding it less available than before — longer waits, limited availability, output spoken for ahead of time, access that must be secured rather than assumed — and management describes responding to that scarcity from a position of choice: holding or raising price, being selective about which business to take, letting customers wait rather than over-expanding, or otherwise letting the shortage improve the terms on which the company does business. The scarcity may arise from any direction — the company's own deliberate restraint, industry capacity limits, slow-to-add supply, or demand simply outrunning what exists — and the form may vary widely across industries. What matters is that management presents the tightening as real and current, and treats it as something that strengthens the company's hand rather than as a problem to be urgently fixed. Answer NO if the company is comfortably supplying everything asked of it, or is chiefly working to stimulate, win, or defend demand. NO if the shortage described is of things the company BUYS — components, materials, freight, labor — that constrain its own shipments, without buyers competing for the company's own scarce output. NO if management describes the tightness purely as a problem it is urgently fixing, with no sense that it is improving the company's pricing, selectivity, or terms. NO if the scarcity is only anticipated for the future, or is presented as a brief disruption already resolved. NO if management merely reports strong demand or a good quarter without any sense that availability is tightening relative to demand. NO if the idea appears only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
PRA ProAssurance Corporation Q1 2024 2024-05-11 D
AES The AES Corporation Q1 2024 2024-05-03 C+
PDS Precision Drilling Corporation Q1 2024 2024-04-25 B
LEGH Legacy Housing Corporation Q4 2023 2024-03-18 C
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
DAL Delta Air Lines, Inc. Q2 2023 2023-07-13 A
UAL United Airlines Holdings, Inc. Q4 2022 2023-01-18 B
STM STMicroelectronics NV Q3 2018 2018-10-24 C+
ESS Essex Property Trust, Inc. Q2 2018 2018-08-03 B+
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
RACE Ferrari N.V. Q3 2017 2017-11-02 C+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

LEGH · Q4 2023 → YESThe question is: Does management convey that WHAT THE COMPANY SELLS IS BECOMING HARDER FOR BUYERS TO OBTAIN — availability tightening — AND that management is allowing that tightening to work in the c...YES The transcript shows management explicitly holding production levels steady to build backlog rather than ramping output, while continuing to hold pricing levels. Duncan Bates states: “We have held pricing levels and held production levels as we continue to build a backlog across the manufacturing plants” and later “we decided, hey, let's keep production where it is and keep building the backlog.
STM · Q3 2018 → YESThe question is: Does management convey that WHAT THE COMPANY SELLS IS BECOMING HARDER FOR BUYERS TO OBTAIN — availability tightening — AND that management is allowing that tightening to work in the c...YES The transcript shows management describing current shortages and a "stretched supply chain" for their own products (especially Automotive and Power Discrete), with backlogs confirming demand outrunning availability. They explicitly note pricing upside from the fractured supply situation in Power and treat the tightness as a positive dynamic rather than an urgent problem to fix.
ALL · Q3 2023 → YESThe question is: Does management convey that WHAT THE COMPANY SELLS IS BECOMING HARDER FOR BUYERS TO OBTAIN — availability tightening — AND that management is allowing that tightening to work in the c...YES The transcript shows management explicitly restricting new business growth in unprofitable states (California, New York, New Jersey down 75% in new applications) and describing this as part of the profit improvement plan that is working in their favor by improving margins and allowing selective removal of restrictions only where target returns are achieved.

More from the question bank

Proof-point cadenceSomeone else already paid for the growthCorrecting the record with current factsLocus of control flipAhead of their own clockBetting on one customer's rampAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.